Gilead Sciences mentioned Tuesday it was talking with chemical and drug manufacturers to produce its experimental COVID-19 drug remdesivir for Europe, Asia, and the creating world via at least 2022.
The drug producer didn’t disclose details concerning the companies.
With several nations across the globe reeling from the virus pandemic, interest in remdesivir has been high as there are currently no permitted treatments or vaccines for COVID-19, the respiratory illness brought on by the novel coronavirus.
Gilead last week received the U.S. Food and Drug Administration’s emergency use authorization for utilizing remdesivir as a remedy against COVID-19 after the drug producer provided data showing the drug had helped COVID-19 sufferers.
Gilead further stated Tuesday it was negotiating long-term licenses with several generic drugmakers in India and Pakistan to produce remdesivir for emerging nations and that it would present technology to aid the production.
One of Bangladesh’s largest drug producers, Beximco Pharmaceuticals, will begin remdesivir production this month.
Remdesivir was previously obtainable only for sufferers enrolled in medical trials or those cleared to get the drug under expanded use and compassionate use programs.
Gilead, which has already stated it would donate the first 1.5 million doses of remdesivir, also previously stated it was focused on making the drug accessible and affordable to as many people as possible upon clearance.